Net margin is calculated as Net Income divided by its Revenue. Editas Medicine's Net Income for the
three
months ended in Mar. 2026 was $-24.98 Mil. Editas Medicine's Revenue for the
three
months ended in Mar. 2026 was $2.83 Mil. Therefore, Editas Medicine's net margin for the quarter that ended in Mar. 2026 was -882.44%.
The historical rank and industry rank for Editas Medicine's Net Margin % or its related term are showing as below:
EDIT'
s Net Margin % Range Over the Past 10 Years
Min: -1605.53 Med: -692.58 Max: -127.82
Current: -281.59
EDIT's Net Margin % is ranked worse than 64.41% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs EDIT: -281.59
Editas Medicine (NAS:EDIT) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Editas Medicine Net Margin % Related Terms
Editas Medicine Net Margin % Historical Data
* Premium members only.
The historical data trend for Editas Medicine's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Editas Medicine's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's Net Margin % distribution charts can be found below:
* The bar in red indicates where Editas Medicine's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Editas Medicine (EDIT) has a Net Margin % of -882.44% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Editas Medicine and its competitors. According to the industry distribution chart, Editas Medicine ranks #610 out of 947 companies in the Biotechnology industry, placing it in the top 64.4%.
Is Editas Medicine's Net Margin % too high?
Editas Medicine's current Net Margin % is -882.44%. Based on the distribution chart, Editas Medicine ranks #610 out of 947 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Editas Medicine has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's Net Margin % compare to PRTA and XOMA?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #610 out of 947 companies for Net Margin %. This places Editas Medicine in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Editas Medicine and its competitors. Editas Medicine's current Net Margin % is -882.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.92, compared to a current price of $2.81 — trading 46.1% above its estimated fair value. The current Net Margin % is -882.44%. Editas Medicine's overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Editas Medicine (EDIT), the current Net Margin % is -882.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Editas Medicine (EDIT) Overvalued in 2026?
Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued.
The current stock price of $2.81 is trading 46.1% above its estimated GF Value™ of $1.92.
GuruFocus considers Editas Medicine to be Significantly Overvalued.
Key valuation signals for EDIT:
Net Margin %: -882.44%
GF Value™: $1.92 vs. price of $2.81 (46.1% above fair value)
No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
51GF Score
Get the complete analysis for EDIT
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDIT has been successfully added to your 
